Hematology

Hematologic conditions and cancers in children can differ from those seen in adults in disease biology, presentation, treatment protocols, and long-term effects. Many hematologic laboratory measurements also require age-appropriate reference ranges, and medication selection or dosing may vary with the patient's age, size, diagnosis, and treatment protocol. Pediatric hematology/oncology expertise can therefore be important when disputed care involves a child with a blood disorder, leukemia, another hematologic malignancy, or a complication of treatment.

The review may compare platelet counts, coagulation studies, factor levels, medications, prior bleeding or clotting history, procedures, transfusions, and the timing of symptoms. In a hemophilia case, the expert may also consider the specific clotting-factor deficiency, factor replacement therapy, development of inhibitors, and whether the laboratory and clinical course are consistent with the proposed mechanism of bleeding.

Trends in white blood cells, red blood cells, platelets, peripheral blood findings, and bone marrow results can help trace when hematologic abnormalities emerged and how they changed during treatment. Where available, flow cytometry, cytogenetic, molecular, and pathology findings may provide additional information about the leukemia itself. Comparing those results with treatment records, infections, transfusions, and medication effects can help distinguish changes associated with the malignancy from therapy-related or other hematologic processes.